RxDoctor Payments Data

Denise Kidder, APRN

Family · Evansville, INNPI 1184003501

Payments from drug & device makers

$6,898in general payments, 2019–2025

Across 409 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$883
  • Otsuka America Pharmaceutical, Inc.$742
  • AbbVie$617
  • Novo Nordisk$435
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$430
  • Amgen$296
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,74498%
  • Education$1542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,898 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$1,314,044
Medicare patients
147
Services billed
102,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$43,984
OzempicSemaglutide36$34,515
LinzessLinaclotide27$22,823
RexultiBrexpiprazole11$20,928
VascepaIcosapent Ethyl17$12,477
TrintellixVortioxetine Hydrobromide12$11,535
EliquisApixaban11$10,841
FarxigaDapagliflozin Propanediol12$10,310
NexlizetBempedoic Acid/Ezetimibe12$8,619
BelsomraSuvorexant19$8,037
Ondansetron Hcl18$5,113
Lamotrigine ErLamotrigine11$2,488
Insulin Lispro Kwikpen U-100Insulin Lispro16$1,940
Albuterol Sulfate HfaAlbuterol Sulfate64$1,302
Omeprazole63$696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$186$43,98440 claims
Novo NordiskOzempic$435$34,51536 claims
AbbVieLinzess$617$22,82327 claims
Otsuka America Pharmaceutical, Inc.Rexulti$742$20,92811 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$230$11,53512 claims
PfizerEliquis$77$10,84111 claims
AstraZenecaFarxiga$209$10,31012 claims
Esperion Therapeutics, Inc.Nexlizet$77$8,61912 claims
MerckBelsomra$107$8,03719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →